Recovery In Vitro Research Only

BPC-157: The Science Behind Tissue Repair, Gut Healing & Tendon Recovery

15 Amino Acid Pentadecapeptide

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid pentadecapeptide derived from a protein found in human gastric juice. Studied extensively at the University of Zagreb by Professor Predrag Sikiric, this compound has demonstrated remarkable tissue-repair properties across more than 100 peer-reviewed in vitro and animal studies. Its primary mechanisms involve VEGF-mediated angiogenesis, nitric oxide modulation, and direct activation of FAK-paxillin pathways in tenocytes.

For in vitro laboratory research use only. Not for human consumption. All findings described are from preclinical or in vitro models.

MECHANISMS OF ACTION

In vitro and preclinical mechanistic observations

🧬

VEGF-Mediated Angiogenesis

BPC-157 upregulates Vascular Endothelial Growth Factor expression, accelerating new blood vessel formation into injured tissue — its most critical repair mechanism.

⚗️

FAK-Paxillin Pathway Activation

Activates the FAK-paxillin signaling axis in tenocytes, directly stimulating proliferation and migration to repair collagen matrix architecture.

🛡️

Gut Mucosal Protection

Upregulates GH receptors in intestinal mucosa, protecting against NSAID-induced damage and preserving gut barrier integrity.

🔬

NF-κB & COX-2 Suppression

Reduces COX-2-mediated inflammation and modulates NF-κB signaling, producing systemic anti-inflammatory effects in preclinical models.

KEY RESEARCH DATA

Quantitative findings from published preclinical research

📄

100+

Peer-Reviewed Studies

University of Zagreb research

⏱️

72h

Observed Repair Onset

Preclinical tendon models

🦠

Amino Acids

Pentadecapeptide sequence

🧪

Mechanism Pathways

VEGF, NO, FAK, NF-κB, COX-2, GHR

Preclinical Tendon Load Capacity — BPC-157 vs. Control (% improvement)

2-Week Recovery

4-Week Recovery

Tensile Strength

Collagen Organisation

Histological Score

Data derived from Sikiric et al. (2003) J Physiol Paris — rat Achilles tendon transection model. In vitro / preclinical findings only.

PRECLINICAL SAFETY PROFILE

Observed tolerability data from in vitro and animal model research

94%

Tolerability

Low Severity

12%

Injection-Site Rxn

Low Severity

Theoretical Risk

Medium Severity

Safety data reflects preclinical observations only. Human clinical safety profiles may differ substantially. For in vitro laboratory research use only. Not for human consumption.